EyePoint Pharmaceuticals Reports 90% Revenue Decline and $94.5 Million Net Loss in Q2 2026

EyePoint Pharmaceuticals, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated total revenues of $507,000 for the three months ended June 30, 2026, a sharp decline of 90% compared to $5.3 million in the same period last year. For the first half of 2026, revenues totaled $1.2 million, down 96% from $29.8 million in the prior year. The decrease was primarily attributed to the recognition of deferred revenue from a previous licensing agreement for the YUTIQ® product rights, which had a substantial impact on the company's revenue streams.

Operating expenses also rose significantly, totaling $97.9 million for the second quarter of 2026, a 45% increase from $67.6 million in the same quarter of 2025. The increase was largely driven by a 51% rise in research and development expenses, which reached $83.6 million, reflecting ongoing Phase 3 clinical trials for the company's lead product candidate, DURAVYU™. General and administrative expenses also increased by 20% to $14.2 million, primarily due to higher personnel costs, including stock-based compensation. The net loss for the quarter was $94.5 million, compared to a loss of $59.4 million in the same quarter of the previous year.

In terms of strategic developments, EyePoint has been actively advancing its clinical pipeline, particularly with DURAVYU™, which is being evaluated for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). The company completed enrollment in pivotal Phase 3 trials for DME in July 2026, with initial data expected in the fourth quarter of 2027. Additionally, EyePoint appointed Dr. Tarek S. Hassan as Chief Strategic Science Officer in July 2026, indicating a focus on strengthening its leadership in research and development.

The company’s liquidity position remains a critical focus, with cash, cash equivalents, and marketable securities totaling $180.5 million as of June 30, 2026. This amount is expected to fund operations into the fourth quarter of 2027. However, EyePoint has acknowledged the ongoing need for additional funding to support its clinical trials and operational expenses. The company has a history of operating losses and relies on equity financing and collaboration agreements to sustain its operations. The ability to secure future funding remains uncertain, and management has indicated that without adequate financing, it may need to delay or reduce its research and development programs.

Looking ahead, EyePoint anticipates continued operating losses as it progresses with its clinical trials and seeks regulatory approvals for its product candidates. The company is committed to advancing its pipeline and exploring potential collaborations or acquisitions to enhance its product offerings. However, the success of these initiatives will depend on various factors, including market conditions, clinical trial outcomes, and the company's ability to secure necessary funding.